Device Trial Radar · NCT01518322
Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms
Last checked: Nov 19, 2026Latest source record: Aug 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
235
Actual
Start
Nov 2011
Primary completion
Feb 2012
Study completion Feb 2012
Sponsor
- Lead sponsor
- Aerocrine ABNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 26, 2012
Design
- Study type
- Observational
- Who can join
- All sexes, from 7 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Overall Aim: To better understand the diagnostic process for prolonged respiratory events and determine the potential role of FeNO in assessing the possibility of asthma as the symptoms etiology. Study Objectives: The specific objectives of this study are to: * Determine the frequency of ICS prescription for the treatment of non-specific lower respiratory symptoms. * Determine the frequency of asthma diagnosis as an etiology for the non-specific lower respiratory symptoms. * Explore the value of FeNO in identifying asthma as the etiology of the non-specific lower respiratory symptoms. Number of Subjects: It is anticipated that up to approximately 3,000 patients will be asked to complete the brief screening questionnaire that will be used to identify up to approximately 280 eligible patients who meet the study inclusion/exclusion criteria during a (approximately) 4 to 6 week study enrollment period. Reference Product: NIOX MINO® Duration of the participants involvement in the investigation: Single Visit Performance assessments: Fractional Exhaled Nitric Oxide (FeNO) Measurements will be performed using the NIOX MINO® device according to "Instructions for NO measurements" which will be provided to each Investigative site prior to patient enrollment. Safety Assessments: The Investigator is responsible for the detection, reporting, and documentation of events meeting the definition of an Adverse Event (AE) and/or Serious Injuries as provided in this clinical investigation plan from the time of informed consent/assent and during the study period. Criteria for Evaluation: The relationship(s) between FeNO and both the diagnosis of asthma and prescription of ICS will be explored by correlation, measures of concordance and logistic modeling.
Conditions
- Asthma
Interventions
NIOX MINO®Device
Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relationship Between FeNO and the Diagnosis of AsthmaTime frame: Single-visit, one (1) FeNO measurement. One (1) timepoint (Day 1)
- Relationship Between FeNO and the Prescription of ICS in Primary Care PracticesTime frame: Single-visit, one (1) FeNO measurement. One (1) timepoint (Day 1)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Olmstead Medical Center Byron
Byron, Minnesota
Olmstead Medical Center Chatfield
Chatfield, Minnesota
Olmstead Medical Center Pine Island
Pine Island, Minnesota
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.